In conclusion, we have demonstrated that a 24-mer peptide targeting the VEGF165-binding site on the novel VEGF receptor, NP-1, antagonises the autocrine antiapoptotic effects of VEGF on breast carcinoma cells. Here, NRP1 is linked to breast carcinoma.